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Clinical utility of androgen receptor 
gene aberrations in circulating 
cell-free DNA as a biomarker for 
treatment of castration-resistant 
prostate cancer
takayuki sumiyoshi1, Kei Mizuno1,2, toshinari Yamasaki1, Yu Miyazaki1, Yuki Makino1, 
Kosuke okasho1, Xin Li1, Noriaki Utsunomiya1, takayuki Goto1, takashi Kobayashi1, 
Naoki terada3, takahiro Inoue1, tomomi Kamba4, Akihiro Fujimoto2, osamu ogawa1 & 
shusuke Akamatsu1
the therapeutic landscape of castration-resistant prostate cancer (CRpC) has rapidly expanded. there is 
a need to develop noninvasive biomarkers to guide treatment. We established a highly sensitive method 
for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma circulating 
cell-free DNA (cfDNA) and evaluated the AR statuses of patients with CRpC. AR amplification was 
detectable in VCap cell line (AR amplified) genomic DNA (gDNA) diluted to 1.0% by digital PCR (dPCR). 
AR mutation were detectable in LNCap cell line (AR T878A mutated) gDNA diluted to 0.1% and 1.0% 
by dpCR and target sequencing, respectively. Next, we analyzed AR status in cfDNA from 102 patients. 
AR amplification and mutations were detected in 47 and 25 patients, respectively. As a biomarker, 
AR aberrations in pretreatment cfDNA were associated with poor response to abiraterone, but not 
enzalutamide. In serial cfDNA analysis from 41 patients, most AR aberrations at baseline diminished 
with effective treatments, whereas in some patients with disease progression, AR amplification or 
mutations emerged. the analysis of AR in cfDNA is feasible and informative procedure for treating 
patients with CRpC. cfDNA may become a useful biomarker for precision medicine in CRpC.
Prostate cancer (PCa) is the second most frequently diagnosed cancer among males worldwide. PCa is driven by 
androgen receptor (AR) signaling, with the standard treatment for advanced disease being androgen depriva-
tion therapy. However, most patients eventually gain resistance and develop castration-resistant prostate cancer 
(CRPC). The primary mechanism underlying CRPC is reactivation of the AR pathway. This includes de novo 
androgen synthesis by cancer cells, AR gene (AR) amplification and mutations, and generation of truncated splice 
variants lacking the ligand binding domain (LBD)1,2. Potent AR axis-targeted agents (ARATs) such as abiraterone 
and enzalutamide prolong survival of patients with CRPC; however, nearly a third of the patients show primary 
resistance to ARATs3,4. Taxanes such as docetaxel and cabazitaxel are also known to prolong survival of patients 
with CRPC. In addition, multiple AR targeting and non-AR targeting agents are currently in development. Given 
the wide selection of treatments for CRPC, it is important to optimize the treatment sequence and promote pre-
cision medicine based on molecular and genetic biomarkers.
In the past 5 years, several large studies have identified recurrent somatic mutations, copy number alterations, 
and chromosomal rearrangements from CRPC metastatic sites5–7. However, it is difficult to routinely obtain tissue 
in PCa, which predominantly metastasizes to bone. Even if successfully collected, the sample may contain low 
tumor volume and not amenable to genetic studies. Furthermore, CRPC is a highly heterogeneous disease, and 
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biopsy of a single site may not reflect the molecular characteristics of all tumor sites. As an alternative to tissue 
biopsy, there is a growing interest in liquid biopsies such as circulating tumor cell (CTC) and circulating cell-free 
DNA (cfDNA). In PCa, several groups have recently shown the association of AR amplification and mutations 
in plasma cfDNA with poor responses to abiraterone and enzalutamide in patients with CRPC8–12. However, 
predictive values of these aberrations remain controversial13. Moreover, there is still a technical challenge to ana-
lyze highly fragmented (150–200 bp) and diluted (nanograms per 1 ml plasma) cfDNA and reliably detect those 
shed from tumor cells (circulating tumor DNA; ctDNA) which generally comprises less than 10% of cfDNA. 
Herein, we established a robust method to analyze the AR copy number (CN) and mutations in plasma cfDNA by 
combined use of digital PCR (dPCR) and multiplex PCR based target sequencing. We analyzed the AR status of 
Japanese patients with CRPC to evaluate the utility of cfDNA as a novel biomarker.
Results
the development of AR CN and mutations analysis in cfDNA. AR CN analysis by dPCR was first 
tested using VCaP (AR amplified) and LNCaP (AR CN neutral) cell lines. AR CN in VCaP genomic DNA (gDNA) 
and LNCaP gDNA were 25.02 copies/µl and 0.94 copies/µl, respectively (Supplementary Fig. S1a). In serial dilu-
tion, AR amplification could be detected when VCaP gDNA was diluted by LNCaP gDNA to 1.0% (Fig. 1a). In 
vivo, AR amplification could be detected in plasma cfDNA from mice implanted with VCaP. In comparison, AR 
CN in cfDNA from mice implanted with LNCaP was 1.07 copies/µl, which was not statistically different from that 
in LNCaP gDNA (p = 0.064). These results confirmed the establishment of a successful assay for CN analysis in 
cfDNA (Supplementary Fig. S1b).
Similarly, AR mutations analysis by dPCR was tested using cell lines. T878A could be detected in LNCaP 
(AR T878A mutated) gDNA and cfDNA from mice implanted with LNCaP, but not in VCaP (AR wild type) 
(Supplementary Fig. S2a–d). In serial dilution, T878A could be detected even when LNCaP gDNA was diluted to 
0.1% (Fig. 1b,c). By target sequencing, T878A could be detected when LNCaP gDNA was diluted to 1.0%, but not 
at 0.5% (Fig. 1d). In the range of 0.5% to 1.0%, other mutation candidates that have not been reported previously 
in LNCaP were detected (Supplementary Table S1). However, these candidates were undetectable when a different 
DNA polymerase was used for library preparation. Mutation candidates in the range of 0.5% to 1.0% were also 
detected in cfDNA from 3 healthy males, two of which corresponded to the variants that became undetectable in 
LNCaP after changing DNA polymerase (Supplementary Table S2), indicating false positive detections. Therefore, 
for mutation analysis by target sequencing in human cfDNA samples, we set a cut-off of variant allele frequency 
(VAF) of 1.0%. However, for the mutations in known hot spots (L702H, W742C, W742L, H875Y and T878A), we 
set the cut-off at 0.5%, and validated the mutations with dPCR.
the evaluation of AR status in plasma cfDNA from patients with CRpC. One hundred two patients 
with CRPC were recruited, and a total of 147 blood samples were collected (45 were collected serially during 
treatment) (Supplementary Fig. S3). Of 102 baseline cfDNA samples, 83 were collected upon biochemical or 
clinical progression to ongoing treatment, and 19 were collected during response to treatment. Baseline patient 
characteristics are shown in Table 1. Notably, many patients had histories of treatments with various conventional 
anti-androgens and estrogens since the majority of them were already castration-resistant before abiraterone and 
enzalutamide became widely available in Japan. The median cfDNA concentration from patients with CRPC 
[11.36 ng/ml (range: 2.84–1464)] was significantly higher than that from healthy males [5.52 ng/ml (range: 3.02–
12.96)] (p < 0.01) (Supplementary Fig. S4).
AR CN in patients with CRPC ranged from 0.94 copies/µl to 165.8 copies/µl, and 47 of 102 (46.1%) patients 
had AR amplification at the time of baseline sample collection (Fig. 2a). Importantly, AR amplification was 
detected in 46 of the 83 (55.4%) patients who had baseline samples collected at disease progression, but in only 1 
of the 19 (5.3%) patients whose samples were collected during the response to treatment. AR target sequencing 
in all cfDNA samples was successfully performed, and median coverage of each amplicon was >10000×. AR 
LBD mutations were identified in 25 of 102 (24.5%) patients (Fig. 2b). Nine of these 25 patients had 2 mutations, 
and each VAF ranged from 0.56% to 24.59%. The rate of AR mutation in samples collected at disease progression 
(21/83, 25.3%) was not significantly different from that sampled during response to treatment (4/19, 21.1%). Most 
of the mutations were located at known hot spots. The F877L mutation is reportedly associated with resistance to 
enzalutamide14,15 and was detected in one sample collected upon development of resistance to enzalutamide. Four 
additional mutations (R630W, R630Q, V716M and P893S) were identified. R630Q and V716M were identified at 
a relatively high VAF (3.25% and 3.64%, respectively). Importantly, we determined that V716M was located near 
the known LBD hot spots in the 3D structure of the AR protein, suggesting that this amino acid change might 
alter ligand binding of AR and associates with treatment resistance (Fig. 2c). R630Q and V716M were identified 
in cfDNA collected at the time of resistance to abiraterone and bicalutamide, respectively. Both patients subse-
quently responded to enzalutamide.
AR status in cfDNA was compared to matched CRPC tissue gDNA in 12 patients (Supplementary Table S3). 
In AR CN analysis, concordance was confirmed in 7 of 12 (58.3%) patients. All 5 patients with discordance 
showed AR amplification in gDNA from the prostate, but not in cfDNA. In AR mutation analysis, 10 of 12 (83.3%) 
patients showed completely concordant results. Patient KU-112 had W742L in cfDNA, but not in gDNA from the 
prostate, possibly reflecting tumor heterogeneity.
the association between AR aberrations in cfDNA and clinicopathological factors. The sum-
mary of AR status in cfDNA for each patient is presented in Fig. 3. Sixty-one of 102 (59.8%) patients had AR 
aberrations (amplification and/or mutations) in cfDNA. Eleven of these 61 patients had both AR amplification 
and mutations, which was inconsistent with other reports that indicated a tendency toward mutual exclusiv-
ity6,11. Clinicopathological factors associated with AR aberrations in cfDNA were analyzed in 83 patients who 
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underwent blood collection at disease progression. Fifty-six of the 83 (67.5%) patients had AR aberrations, and we 
showed that Hb ≤ LLN, cfDNA concentration, increasing number of prior systemic treatments and resistance to 
estramustine phosphate, abiraterone, enzalutamide or docetaxel were significantly associated with the presence of 
AR aberrations in cfDNA by univariate analysis (Supplementary Table S4). Since only 8 patients were treated with 
Figure 1. The sensitivity of copy number (CN) and mutation analysis by digital PCR (dPCR) and target 
sequencing. (a) LNCaP (AR CN neutral) genomic DNA (gDNA) was spiked with VCaP (AR amplified) gDNA 
in serial dilution. AR amplification could be detected by dPCR even when VCaP gDNA was diluted to 1.0%. 
Stars (p < 0.01* and p = 0.015**) indicate that AR CN in diluted VCaP gDNA are significantly higher than 
that in LNCaP gDNA by the Student’s t-test (n = 3). (b) gDNA from healthy males (AR wild type) was spiked 
with LNCaP (AR T878A mutated) gDNA in serial dilution. The AR T878A mutation could be detected at 0.1% 
dilution by dPCR. Stars (p < 0.01* and p = 0.014**) indicate that the mutation rates in diluted LNCaP gDNA 
were significantly higher than those observed in gDNA from healthy males by the Student’s t-test (n = 3). (c) 
Scatter plots of dPCR analysis for the gDNA from healthy males spiked with 0.1% LNCaP gDNA. The mutation 
detection rate was 0.09%. The blue dots show positive droplets for the AR T878A mutation. The red dots show 
positive droplets for the AR wild type. The yellow dots show empty droplets. (d) AR target sequencing for gDNA 
from healthy males spiked with LNCaP gDNA in serial dilution. AR T878A mutation could be detected up to 
1.0% dilution. All error bars indicate standard deviation.
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All patients (n = 102)
Age, median (range), years 74 (48–96)
PSA, median (range), ng/ml 15.8 (0.008–2082)







Site of Metastasis, No. (%)





ECOG PS, No. (%)
  0–1 73 (71.6)
  ≥2 29 (28.4)
Time from starting ADT, median (range), months 55.9 (4.1–207.6)
Time from CRPC diagnosis, median (range), months 24.0 (0–140.7)
Hemoglobin
  Median (range), g/dl 12.4 (6.6–15.7)
  <LLN No. (%) 19 (18.6)
ALP
  Median (range), U/L 275.5 (78–3208)
  ≥360, No. (%) 32 (31.4)
LDH
  Median (range), U/L 204 (77–2280)
  ≥227, No. (%) 29 (28.4)











   Paclitaxel and Carboplatin 2 (2.0)
No. of resistance to anti-androgen therapy/chemotherapy, median (range) 3 (0–9)











   Paclitaxel and Carboplatin 3 (2.9)
Table 1. Patients’ Characteristics at baseline Abbreviations: PSA, prostate-specific antigen; ECOG PS, Eastern 
Cooperative Group Performance Status; ADT, androgen deprivation therapy; CRPC, castration-resistant 
prostate cancer; ALP, Alkaline Phosphatase; LDH, Lactate dehydrogenase; LLN, Lower Limit of Normal.
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chemotherapy immediately prior to baseline sample collection, there was no statistical difference in the frequency 
of AR aberrations between samples collected after hormone therapy progression and chemotherapy progression 
(Supplementary Table S4).
the evaluation of AR aberrations in cfDNA as a biomarker of response to abiraterone and enza-
lutamide. Of the 102 patients, 81 switched treatment after baseline cfDNA collection. Fourteen, 24 and 25 
patients were initiating treatment with abiraterone, enzalutamide, and docetaxel/cabazitaxel, respectively. The 
clinical outcomes of each treatment were evaluated by the percentage of change in prostate-specific antigen (PSA) 
from baseline at 12 weeks (or earlier for those who discontinued treatment) and PSA progression-free survival 
(PSA-PFS) according to Prostate Cancer Working Group 2 Criteria16. For abiraterone, patients with AR mutations 
known to be associated with drug resistance (L702H, T878A or H875Y)8,9 or those with AR amplifications had 
poorer PSA response compared to patients without these aberrations (Fig. 4a). In the patients with AR CN neutral 
and mutations at other locations (R630W, W742C, W742L and P893S), PSA was reduced by more than 80.0%. 
Median PSA-PFS in the patients with these aberrations also tended to be shorter than those without the aber-
rations (median 66.5 days versus 342 days, p = 0.049 by Wilcoxon test and p = 0.087 by log-rank test) (Fig. 4b). 
On multivariable Cox proportional hazard analysis, AR aberrations was independently significantly associated 
with PSA-PFS (Supplementary Table S5). In contrast, in the enzalutamide group, PSA change and PSA-PFS in the 
patients with AR amplification were not significantly different from those without AR amplification (median 205 
days versus not reached, p = 0.212 by Wilcoxon test and p = 0.117 by log-rank test) (Fig. 4c,d and Supplementary 
Table S6). In the docetaxel/cabazitaxel group, almost all patients had AR aberrations, and PSA change did not 
differ relative to AR status (Supplementary Fig. S5).
Figure 2. Landscapes of AR copy number (CN) and mutations in cfDNA from patients with CRPC (n = 102) 
at baseline. (a) AR amplification was defined as AR CN > 1.54 copies/μl based on AR CN in cfDNA from 
healthy males. The red lines show the cases with AR amplification, and the blue lines show the cases with no 
AR amplification. (b) The locations of the mutations identified are mapped on the AR gene. Each colored circle 
represents a single mutation in a single sample. The red letters indicate the known hotspots on ligand binding 
domain (LBD). (c) Structured 3D image of an AR protein showing that V716M is located in the proximity of the 
known hotspots in LBD. VAF, variant allele frequency.
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serial analysis of AR status in cfDNA. In 41 patients, blood samples were collected multiple times during 
treatment to track AR status (Fig. 5). cfDNA samples from 37 patients were collected twice (at baseline and at 
the time of response or resistance to treatment), whereas 4 patients had cfDNA collected three times, at baseline, 
during response and at resistance to treatment. Thirteen of the 41 patients had cfDNA analyzed at baseline and 
during response to treatment. Among them, 7 patients had AR amplifications at baseline; however, amplification 
became undetectable in 6 patients during treatment with enzalutamide (n = 3), abiraterone (n = 1), docetaxel 
Figure 3. Integrated data of AR copy number and mutations in cfDNA from patients with CRPC (n = 102) 
at baseline. The longitudinally placed boxes indicate each sample. Sixty-one of 102 (59.8%) patients had AR 
aberrations (amplification and/or mutations) in cfDNA. Blue, red and green squares indicate AR aberrations, 
amplifications, and mutations, respectively.
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(n = 1) and cabazitaxel (n = 1). In one patient, AR amplification was newly detected at the time of response to 
treatment with paclitaxel and carboplatin. AR mutations were detected in 5 patients at baseline, all of which 
became undetectable during the patients’ responses to abiraterone (n = 2), enzalutamide (n = 1), docetaxel (n = 1) 
and paclitaxel and carboplatin (n = 1).
Of the 41 patients, we collected blood samples from 32 patients at baseline and at the time of resistance to 
treatment, including 4 patients who also had cfDNA analyzed while they were responding to therapy. Of the 22 
patients with AR amplification at baseline, amplification remained detectable in 19 patients at the time of resist-
ance, whereas AR amplification became undetectable in 3 patients (KU-053, KU-055 and KU-057). Among them, 
KU-053 and KU-055 were treated with enzalutamide after blood collection at baseline, and AR amplification 
Figure 4. Clinical outcomes of abiraterone (n = 14) and enzalutamide (n = 24) therapy according to AR 
aberrations. (a) Waterfall plot of %PSA change from baseline at 12 weeks stratified by AR status for abiraterone. 
(b) Kaplan-Meier analysis of PSA-PFS in patients treated with abiraterone. Median PSA-PFS in the patients with 
AR amplification, L702H, H875Y or T878A in cfDNA tended to be shorter than those without these aberrations 
(median 66.5 days versus 342 days, p = 0.049 by Wilcoxon test and p = 0.087 by log-rank test). (c) Waterfall plot 
of %PSA change from baseline at 12 weeks stratified by AR status for enzalutamide. (d) Kaplan-Meier analysis of 
PSA-PFS in patients treated with enzalutamide. Median PSA-PFS was not significantly associated with AR status 
in cfDNA (median 205 days versus not reached, p = 0.212 by Wilcoxon test and p = 0.117 by log-rank test).
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became undetectable during their response, which remained undetectable at the time of progression. In patient 
KU-055, the AR mutation (H875Y), whose VAF at baseline was 21.3%, also became undetectable during treat-
ment with enzalutamide and remained undetectable at progression. Intriguingly, this patient subsequently 
responded to abiraterone (Supplementary Fig. S6). Of the 10 patients without AR amplification at baseline, ampli-
fication was newly detected in 8 patients at the time of treatment resistance, suggesting that AR amplification 
arose as an adaptive response to treatment. In mutation analysis, all AR mutations detected at baseline became 
undetectable at progression. The patient with F877L (KU-046) was subsequently enrolled in a clinical trial for a 
vaccine therapy after exhibiting resistance to enzalutamide, and the mutation became undetectable upon pro-
gression to this therapy. T878A, L702H, H875Y, Q641R and D733N were newly detected in 3 patients (KU-020, 
KU-024 and KU-064) during treatment with abiratetone, docetaxel and estramustine phosphate, respectively.
Figure 5. Integrative data of AR status in cfDNA at baseline, while responding to treatment and during 
treatment resistance. The longitudinally placed boxes indicate each sample. Red and green squares indicate 
AR amplification and mutations, respectively. Up and down arrows indicate emergence and regression of AR 
amplification or mutations, respectively.
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Discussion
AR amplification can drive CRPC progression and is present in up to 50% of CRPC tissues. CN analysis in cfDNA 
has been performed by several methods; array comparative genomic hybridization, next generation sequencing 
(NGS), real time PCR and dPCR8–13,17. In the present study, we showed that AR amplification could be detected 
by dPCR even when VCaP gDNA was diluted to 1.0%. The rate of AR amplification in cfDNA from patients 
with CRPC (46.1%) was comparable to that in other reports, suggesting that our method that used dPCR was a 
simple and robust approach to analyze CN in cfDNA. However, the concordance rate of AR amplification status 
between cfDNA and matched tumor tissue gDNA was only 58.3%. All 5 patients with discordant statuses had AR 
amplification detected in gDNA from prostate tissues, but not from matched cfDNA. Notably, all the patients with 
discordance only had low volume bone metastases, raising the possibility that low yield ctDNA was undetectable 
in these cases. In addition, AR CN in 2 patients (KU-112 and KU-116) was near the cut-off line for determining 
amplification and might have been falsely considered no amplification by our criteria. Increasing the sensitivity 
of dPCR technology may aid in detecting AR amplification in future cases.
AR mutations can also drive CRPC progression. Gain-of-function mutations such as L702H, W742C, W742L, 
H875Y and T878A can change ligand binding affinity, which results in increased sensitivity to steroid ligands or 
the conversion of anti-androgens to agonists1,2. AR mutations in cfDNA have been detected by NGS or dPCR8,9,11–
13. NGS can evaluate targeted genes comprehensively; however, its sensitivity is restricted by the inherent detec-
tion limits of NGS technology which are around 1.0%. Digital PCR can detect rare mutations with a prevalence as 
low as 0.1%, however, it can evaluate only one mutation in one PCR reaction. In the present study, we combined 
2 methods: initial screening of LBD mutations by multiplex PCR based target sequencing, followed by dPCR 
confirmation of hotspot mutations whose VAFs were between 0.5%-1.0%. By this approach, many hotspot muta-
tions in the range of 0.5%-1.0% could be validated by dPCR. We did not validate other candidates outside of 
known hotspots; however, it is possible that these candidates also contain important biological information18,19. 
Therefore, efforts are underway to increase the sensitivity and specificity of NGS-based analysis using molecular 
barcodes whose utility have not yet been shown in cases of prostate cancer.
Interestingly, the number of patients with concomitant AR amplification and mutations in this study was 
higher than previously reported. In contrast to many studies in which analysis was performed after 1st or 2nd 
line treatments for CRPC, most of the patients in the present study had been exposed to multiple lines of AR 
axis-targeted treatments which contained anti-androgen therapies hardly used in Western countries (i.e. estra-
mustine phosphate). Exposure to multiple agents targeting the AR pathway might have produced a generation 
of diverse clones with different mechanisms of resistance. In the present study, the number of prior systemic 
treatments and resistance to estramustine phosphate abiraterone, enzalutamide, or docetaxel were significantly 
associated with the presence of AR aberrations in cfDNA; however, resistance to bicalutamide and flutamide were 
not. This indicates that AR aberrations tend to accumulate more after resistance to second line hormonal therapy, 
compared to first line complete androgen blockade.
The utility of AR aberrations in cfDNA as predictors of responses to abiraterone and enzalutamide is still con-
troversial. Initial studies have shown that AR aberrations in cfDNA are linked to poor outcomes with abiraterone 
and enzalutamide8–12, whereas a recent report showed that only strong AR gain (CN ≥ 8 copies) was associated with 
poor responses in patients unexposed to prior treatments for CRPC13. Despite our small sample size, we showed that 
AR amplification, L702H, T878A, or H875Y tended to be associated with poor response to abiraterone, and that AR 
aberrations were not associated with response to enzalutamide. The difference in outcomes between the 2 treatments 
is attributable to the different pharmacological mechanisms of each treatment; abiraterone mostly indirectly blocks 
the AR pathway via androgen biosynthesis, whereas enzalutamide blocks AR directly as an antagonist, and was 
developed to potently block the AR pathway within the context of AR overexpression20,21.
We serially analyzed cfDNA in 41 patients to evaluate dynamic changes in AR status during treatment. Almost 
all amplifications and mutations at baseline became undetectable during the response to treatment, possibly 
reflecting decreased tumor burden11. In some patients, AR amplification and mutations at baseline disappeared 
by the time of progression, possibly indicating that the clones that have gained resistance to previous treatments 
by acquiring AR aberrations were mostly eliminated by the subsequent treatments and became non-dominant 
clones at later progression. Quite intriguingly, in one patient (KU-055) with an AR amplification and H875Y at 
baseline, these aberrations became undetectable by the time of response to enzalutamide and did not re-emerge 
upon acquiring resistance. It is possible that tumor clones with the AR aberrations regressed dramatically by 
exposure to enzalutamide, and the tumor may have eventually acquired resistance to enzalutamide by other 
mechanisms such as increased de novo steroidogenesis through overexpression or mutation of HSD3B122. The 
patient responded to subsequent treatment with abiraterone. Several studies have shown that response to abirater-
one following enzalutamide is limited23,24; however, the present case raises the possibility that, on rare occasions, 
enzalutamide may eradicate the clones with AR aberrations associated with abiraterone resistance and re-sensitize 
the tumor to abiraterone. These observations, if further replicated in future studies, may lead to cfDNA based 
precision medicine in which optimal treatment sequence of CRPC could be guided by liquid biopsy.
This is the first report to evaluate AR status in cfDNA from Japanese patients with CRPC, but we stress that this 
study has several notable limitations. The sample size was small and the heterogeneous patient cohort exhibited 
a variety of baseline characteristics. Larger prospective studies are required. Since the current study focused on 
cfDNA, we did not analyze AR splice variants. In particular, AR-V7 in CTC has been reported to be a prognostic 
biomarker associated with resistance to abiraterone and enzalutamide25. AR overexpression including AR amplifi-
cation or AR genomic structural rearrangements are known to be involved in the expression of AR splice variants26. 
In the future, it will be important to analyze CTC and cfDNA concurrently. Additionaly, a recent study performed 
targeted 72-gene sequencing of cfDNA in patients with CRPC and identified BRCA2 and TP53 mutations in 
cfDNA as predictive biomarkers associated with poor outcomes of abiraterone and enzalutamide13. Genomic aber-
rations other than AR also need to be evaluated within the context of a large cohort of patients with CRPC.
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In conclusion, we have demonstrated that the analysis of AR status in cfDNA, obtained from a minimally inva-
sive blood sample, is feasible and informative for patients with CRPC. AR aberrations in cfDNA have the potential 
to become useful biomarkers in patients with CRPC.
Methods
patient cohort. One hundred two patients with CRPC and 15 healthy males were recruited at Kyoto uni-
versity hospital between September 2015 and November 2017. Of the 15 healthy males, 6 underwent surgery for 
benign prostate hyperplasia before blood collection and were pathologically confirmed to be negative for PCa. 
The remaining 9 were healthy volunteers under the age of 40. All human experiments were approved by the eth-
ical committees at Kyoto University Hospital (G1083). Written informed consent was obtained from all patients. 
All human experiments were performed in accordance with Japanese ethical guidelines for human genome/gene 
analysis research and ethical guidelines for medical and health research involving human subject.
Blood collection and plasma preparation. A blood volume of 8.5–10 ml was collected in an 
EDTA-containing tube, Cell-Free DNA BCT (Streck) or Cell-Free DNA Collection Tube (Roche). Plasma 
was isolated by 2 step centrifugation (1600 g × 15 min and 4100 g × 10 min) within 2 h of blood collection for 
EDTA-containing tubes, or within 7 days for the other tubes. Plasma was stored at −80 °C until cfDNA extraction.
cfDNA and gDNA extraction. cfDNA was extracted from 4–6 ml plasma using the QIAamp Circulating 
Nuclear Acid Kit (Qiagen) according to the manufacturer’s protocol. cfDNA concentration was measured using 
the Qubit 3.0 Fluorometer (ThermoFisher Scientific). Extracted DNA in the first several samples were run on the 
Bioanalyzer 2100 (Agilent Techonologies) to evaluate successful extraction of cfDNA. The DNA exhibited a peak 
at 168 bp which was consistent with that of cfDNA (Supplementary Fig. S7).
gDNA from WBC and tumor tissue was extracted using the DNeasy Blood and Tissue Kit (Qiagen) and the 
QIAamp DNA Mini Kit (Qiagen), respectively. gDNA concentration was measured using the Nanodrop 2000 
spectrophotometer (ThermoFisher Scientific). cfDNA and gDNA were stored at −30 °C.
AR CN analysis. AR CN was analyzed using the QuantStudio 3D Digital PCR system (ThermoFisher 
Scientific). PCR reaction was prepared with 7.5 μl of QuantStudio3D Digital PCR master mix (ThermoFisher 
Scientific), 0.75 μl of Taqman Copy Number Assay for AR (Assay ID: Hs04107225), 0.75 μl of Taqman Copy 
Number Reference assay for RNaseP (Assay ID: 4403326) and cfDNA or gDNA (about 5 ng) in a total volume 
of 15 μl. PCR reaction was loaded onto the QuantStudio 3D Digital PCR Chip (ThermoFisher Scientific) and 
amplified on ProFlex 2x Flat PCR System (ThermoFisher Scientific). The annealing and extension temperatures 
were set at 60 °C, and PCR was run for 39 cycles. After PCR amplification, chips were read on the QuantStudio 
3D Digital PCR Instrument (ThermoFisher Scientific), and a secondary analysis was performed with QuanStudio 
3D Analysis Suit Cloud software (ThermoFisher Scientific). AR CN was calculated using RNaseP as an internal 
control. The cut-off for indicating a positive AR amplification in cfDNA was AR CN > 1.54 copies/μl, which was 
the average plus 2 standard deviations of AR CN in cfDNA obtained from healthy males.
AR mutations analysis. AR mutations were evaluated by 2 approaches: dPCR and target sequencing. To 
detect AR L702H, W742C, W742L, H875Y and T878A mutations by dPCR, validated Taqman SNP genotyping 
assays (Assays ID:C_356510059_10, C_175239651_10 and C_175239649_10) and custom-made Taqman SNP 
genotyping assays were used. The thermal cycling protocol was similar to that used in AR CN analysis; however, 
the annealing and extension temperatures and cycle number were changed to 56 °C and 39 cycles for L702H, 
W742C and W742L, 54 °C and 55 cycles for H875Y, and 62 °C and 39 cycles for T878A.
AR mutations analysis by target sequencing was based on multiplex PCR based deep sequencing11. In brief, 
a total of 11 primer sets spanning the AR LBD were designed and amplified by 3 sets of multiplex PCR which 
was designed to contain non-overlapping target regions (first PCR). KAPA HiFi HotStart ReadyMix (KAPA 
BIOSYSTEMS) and 2 ng of cfDNA were used per reaction. Successful amplification was confirmed by agarose gel 
electrophoresis, and the PCR products were purified by AMPure XP beads (Beckman coulter). Next, overhang 
adapters specifically designed for Illumina sequencing were attached to purified first PCR amplicons using prim-
ers that were used for first PCR with an overhang adapter sequence (second PCR). After purification, the concen-
tration of each set of second PCR amplicons was measured using the Qubit 3.0 Fluorometer, and the amplicons 
were pooled by sample. Finally, a limited cycle amplification was performed to attach sample-specific barcode 
to second PCR amplicons using KAPA HiFi HotStart ReadyMix and the Nextera XT Index Kit (Illumina) (third 
PCR). Agarose gel electrophoresis, purification, and concentration measurement were performed, and the PCR 
products from 96 samples were pooled. Library quality and quantity were evaluated using the Bioanalyzer 2100 
and qPCR according to the Illumina qPCR Quantification Protocol Guide, and the libraries were normalized. 
Sequencing was performed on the Illumina Miseq according to the manufacturer’s instructions. Sequencing run 
included serially diluted LNCaP gDNA as a positive control, and WBC gDNA from 13 patients with CRPC and 
cfDNA from healthy males as negative controls.
The Illumina Miseq generated raw images utilizing MiSeq Control Software v2.2 and base calling through an 
integrated primary analysis software called Real Time Analysis v1.18. The base calls binary was converted into 
FASTQ utilizing illumina package bcl2fastq v1.8.4. Adapters were trimmed away from the reads. Scythe v0.991 
BETA and Sickle programs were used to remove adapter sequences. If the reads were shorter than 36 bp, those 
reads were dropped to produce cleaned data. FASTQ files were aligned against hg19 using Burrows-Wheeler 
Aligner, and the result files were converted to pileup format by samtools. Mutation candidates were determined 
according to the following criteria: (1) VAF of ≥0.5%; (2) minimum supporting reads of 5 at a variant position; 
(3) base quality and mapping quality of ≥20; (4) a minimum read depth of 1000; (5) if a variant was not consistent 
between paired-end reads, both reads were discarded. After mutation candidates calling, candidates were filtered 
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based on the sequence data of WBC gDNA samples. Mean frequency of candidate single nucleotide variant (SNV) 
in WBC samples was considered as error rate. Each SNV allele frequency in cfDNA was compared with the error 
rate by one-sided binomial test, and if the p-value was higher than 0.05, we discarded the SNV. Additionally, we 
examined whether there was a strand bias at candidate SNV positions. We compared the genotypes inferred from 
the positive strand with those from negative strand using the chi-square test. If the p-value was lower than 0.05, 
the SNV was discarded. We further filtered mutation candidates by setting the cut-off VAF of 1.0%. However, for 
known hot spots (L702H, W742C, W742L, H875Y and T878A), variants with VAF of 0.5–1.0% were regarded as 
‘true mutations’ if the SNVs were subsequently validated by dPCR.
The functional analysis of V716M with a 3D permutation method. To interpret a functional impor-
tance of the rare mutation V716M, which is not considered a hot spot in AR, we estimated the location of V716M 
in an AR 3D protein structure (PDB id; 2PIX) with a 3D permutation method27,28. We calculated the average 
distance between hot spots and V716M. We then randomly selected amino acid residues from the AR 3D protein 
structure and calculated the average distance. This procedure was repeated 10,000 times, and a null distribution 
was generated. The p-value of the average distance of the mutations was evaluated using the null distribution.
prostate cancer cell lines. VCaP, LNCaP, 22rv1 and MDA PCa 2b (positive controls for AR amplifica-
tion, T878A, H875Y and L702H, respectively) were purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA). DNA from each cell line was used as a positive control for the development of AR CN and 
mutations analysis. All experiment using cell lines were performed in triplicate.
Mouse xenografts. To confirm successful detection of AR CN and mutations in cfDNA by dPCR, we ana-
lyzed plasma cfDNA from mice implanted with LNCaP or VCaP. A total of 1.0 × 107 cells were injected subcuta-
neously into the bilateral flanks of 6 week-old male BALB/cA Jcl nude (nu/nu) mice (CLEA, Tokyo, Japan) under 
anesthetization. 1.0 ml blood was collected in an EDTA-containing tube, and 2 step centrifugation was performed 
within 2 h. cfDNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen). All experiments involving 
laboratory animals were performed in accordance with the Kyoto University Guidelines for Animal Experiments 
and approved by the Animal Research Committee at Kyoto University Graduate School of Medicine.
statistical analysis. cfDNA concentration between patients with CRPC and healthy males was compared 
using the Mann-Whitney U test. To evaluate the sensitivity of dPCR, AR CN between diluted VCaP gDNA and 
LNCaP gDNA, and the AR T878A mutation rate between diluted LNCaP gDNA and gDNA from healthy males 
were compared using the Student’s t-test. Frequency of AR amplification or mutations in cfDNA between sam-
ples collected at disease progression and while under response to treatment were compared using the chi-square 
test. Clinicopathologic factors associated with AR aberrations in cfDNA at disease progression were analyzed by 
univariate analysis (Fisher’s exact test for categorical variables or logistic regression for continuous variables). 
PSA-PFS rates after starting abiratetone and enzalutamide were estimated using the Kaplan-Meier method and 
the differences between groups were compared using the log-rank test and the Wilcoxon test. Univariate and 
multivariable Cox proportional hazard tests of PSA-PFS after starting abiraterone and enzalutamide were also 
performed. Differences were considered significant when a p-value < 0.05 was obtained. All statistical analyses 
were performed using JMP software version 13.0.0 for Windows (SAS institute Japan, Tokyo, Japan).
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